Walgreen (WAG) Completes $225M Acquisition of BioScrip (BIOS) Assets
Tweet
Share
E-mail
Walgreen Co. (NYSE: WAG) has completed its acquisition of certain assets of BioScrip, Inc.’s (Nasdaq: BIOS) community specialty pharmacies and centralized specialty and mail service pharmacy businesses.
The transaction represents a total deal value of approximately $225 million. Taking into account events that occurred between signing and closing of the transaction, up to an additional $16 million in purchase price may be payable based on events related directly or indirectly to Walgreens retention after the closing of certain business included in the transferred businesses. The acquisition fits the company’s “Well at Walgreens” strategy as it advances community pharmacy and brings additional specialty pharmacy products and services closer to patients. The acquisition also will help grow Walgreens centralized specialty and mail service pharmacy operations.
The transaction represents a total deal value of approximately $225 million. Taking into account events that occurred between signing and closing of the transaction, up to an additional $16 million in purchase price may be payable based on events related directly or indirectly to Walgreens retention after the closing of certain business included in the transferred businesses. The acquisition fits the company’s “Well at Walgreens” strategy as it advances community pharmacy and brings additional specialty pharmacy products and services closer to patients. The acquisition also will help grow Walgreens centralized specialty and mail service pharmacy operations.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Real and RE/MAX Holdings receive court approval for merger
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Cytek faces $56M damages award in Beckman Coulter patent case
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
